Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma

Table 1 Baseline characteristics of the patients

Parameters	Total patients (n = 94)
Gender (n), Male/Female	69:25
Age (yr), ≥ 60 : < 60 yr	46:48
Etiology of HCC (n), HBV: HCV: HBV and HCV co-infection: Alcohol: Cryptogenic	70:11:2:9:2
Antiviral agents (n), Yes/No	60/34
Albumin (g/dL), mean ± SD	3.65 ± 0.52
Bilirubin (mg/dL) , mean ± SD	1.17 ± 0.69
Prothrombin time (INR), mean ± SD	1.21 ± 0.16
AST (IU/L), mean ± SD	55.3 ± 29.7
ALT (IU/L), mean ± SD	44.4 ± 40.4
PLT (× 103/mm3), mean ± SD	97.0 ± 41.6
Controllable ascites : no ascites (n)	26:62
Varices (n), Yes/No	48/46
Child-Pugh score, 5:6:7:8:9	51:16:13:11:3
Chid-Pugh classification, A: B	67:27
Tumor size (cm), > 3.0 : ≤ 3.0	22:72
Tumor number, multiple: single	24:70
Tumor location, bilobar: unilobar	7:87
AFP (ng/mL), > 100: ≤ 100	19:75
Interval between TACE and RFA (d), 0:1:2	27:35:32

AFP: α-Fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; INR: International normalized ratio; PLT: Platelet; RFA: Radiofrequency ablation; SD: Standard deviation; TACE: Transcatheter arterial chemoembolization.